ClinicalTrials.govpublic full text
Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)
hepatocellular carcinoma, first line treatment for hepatocellular carcinoma, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 906619
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.